Tuesday, February 09, 2021 2:52:10 PM
PUB. APP. NO. Title
1 20210032598 ACTIVATION-INDUCED TISSUE-EFFECTOR CELLS SUITABLE FOR CELL THERAPY AND EXTRACELLUAR VESICLES DERIVED THEREFROM
2 20210008150 PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS
3 20200289580 METHODS OF TREATING OCULAR INFLAMMATION AND CHEMICAL INJURIES OF THE EYE WITH EXTRACELLULAR VESICLES
4 20200121727 METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCULAR DYSTROPHY
5 20200054686 METHODS OF TREATING SYSTEMIC GRAFT-VERSUS-HOST DISEASE WITH EXTRACELLULAR VESICLES
6 20190099370 METHOD OF PREVENTING OR TREATING RADIATION-INDUCED DERMATITIS WITH EXTRACELLULAR VESICLES
7 20180321240 METHODS OF MEASURING POTENTIAL FOR THERAPEUTIC POTENCY AND DEFINING DOSAGES FOR AUTOLOGOUS CELL THERAPIES
8 20180282698 GENERATION OF THERAPEUTIC CELLS USING EXTRACELLULAR COMPONENTS OF TARGET ORGANS
9 20180169150 OPTIMIZED METHODS FOR GENERATION OF CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
10 20170363623 METHODS OF MEASURING POTENTIAL FOR THERAPEUTIC POTENCY AND DEFINING DOSAGES FOR AUTOLOGOUS CELL THERAPIES
11 20170360842 PROCESSES FOR PRODUCING STABLE EXOSOME FORMULATIONS
12 20160324930 SYSTEMS AND METHODS FOR THERAPY OF KIDNEY DISEASE AND/OR HEART FAILURE USING CHIMERIC NATRIURETIC PEPTIDES
13 20160317622 Methods of Treatment of Heart Failure With Natriuretic Peptides
14 20160287638 ISCHEMIC TOLERANT CELLS AND CELLULAR FACTORS IN THE TREATMENT OF PERIPHERAL ARTERY DISEASE
15 20160160181 PROCESSES FOR PRODUCING EXOSOMES IN REDUCED OXYGEN CULTURE CONDITIONS
16 20160158291 PROCESSES FOR PRODUCING STABLE EXOSOME FORMULATIONS
17 20160051632 Chimeric Natriuretic Peptide Compositions and Methods of Preparation
18 20150216905 OPTIMIZED METHODS FOR GENERATION OF CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
19 20150190473 THERAPY FOR KIDNEY DISEASE AND/OR HEART FAILURE
20 20150118199 METHODS OF MEASURING POTENTIAL FOR THERAPEUTIC POTENCY AND DEFINING DOSAGES FOR AUTOLOGOUS CELL THERAPIES
21 20120039857 SYSTEMS AND METHODS FOR CARDIAC TISSUE REPAIR
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Capricor&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PG01
DIG THROUGH AND DO YOUR OWN DD ...
Never buy or sell based on my posts.Always consult with a licensed securities professional before you buy or sell any security.My posts are opinions only.Never use them as due diligence.My positions are subject to change without notice.
Recent CAPR News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2024 09:02:22 PM
- Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2024 09:01:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/12/2024 04:46:58 PM
- Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting • GlobeNewswire Inc. • 11/12/2024 02:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/12/2024 05:15:17 AM
- Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13 • GlobeNewswire Inc. • 11/05/2024 02:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/22/2024 09:11:23 PM
- Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares • GlobeNewswire Inc. • 10/18/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/17/2024 08:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 10:01:22 AM
- Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock • GlobeNewswire Inc. • 10/17/2024 10:00:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/16/2024 08:35:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2024 08:25:24 PM
- Capricor Therapeutics Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 10/16/2024 08:17:48 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 10/16/2024 05:31:08 PM
- Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress • GlobeNewswire Inc. • 10/11/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/09/2024 01:16:15 PM
- Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy • GlobeNewswire Inc. • 10/09/2024 01:15:00 PM
- Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress • GlobeNewswire Inc. • 10/04/2024 01:15:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 09/24/2024 08:03:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2024 08:01:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 08:01:08 PM
- Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy • GlobeNewswire Inc. • 09/24/2024 12:00:00 PM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM